Amgen's Xgeva Gains National Institute for Clinical Excellence (NICE) Recommendation for Bone Metastasis

NICE is continuing to recommend Amgen’s Xgeva for certain groups of cancer patients whose disease has spread to their bones. In final draft guidance the watchdog recommends Xgeva (denosumab) as a treatment for people with bone metastases from most solid cancer tumours. Specifically, it recommends the drug in patients with bone metastases from breast cancer and people with bone metastases from solid tumours (other than breast or prostate) that would otherwise be prescribed bisphosphonates. Xgeva works by preventing skeletal-related events from occurring from cancer - but not as an anti-cancer or pain relief treatment.